https://x.com/cremieuxrecueil/status/1967021861730214230?s=19
trump administration could also face pressure from the food industry (as we now know that ozempic has been decreasing demand for food)
1 Like
Very interesting.
I hadn’t considered DIY GLP-1s and their variants.
Seriously considering doing this with Retratrutide.
Seeing lots of reports on its muscle preservation and reduction of visceral fat.
Key questions
-
Potential of addressing metabolic risk, e.g., diabetes or pre-diabetes more directly and with fewer downsides than Metformin?
-
CREMIEUX credibility?
-
DIY safety?
-
Would it really work?
-
Prudent?
Thoughts from medical professionals appreciated.
P.S.
I do use DIY Rapmycin
As I’ve reported across the forum, I already source Rapamycin from Science.bio and use it topically and as an additive to toothpaste.
I’d use it internally if I could get proper entice coated capsules, but haven’t found any I believe I can trust.
DIY Retratrutide seems like a definite next step in biohacking.
My only concern with retatrutide is that potential cardiovascular risk. A common side effect is increased HR, but it’s unclear if that matters in the long run.
Retatrutide doesn’t spare muscle any more (or less) than other incretin mimetics, but it does work better for weight loss for most people. Adequate protein intake and at least some amount of resistance training are essential when on any kind of weight loss regimen, and there’s really no way around that other than taking some sort of anabolic/anti-catabolic compound at the same time if a person is absolutely intent on avoiding exercise (which is a very bad idea IMO).
2 Likes
This is true of all GLP1s
The Twitter post is just a statement, whether that statement is true or false is debatable, since he hasn’t provided his source/justification.
1 Like
Short answer: I’d put the odds around ~75% that the U.S. materially restricts gray-market retatrutide peptide shipments (including from “research peptide” shops like Oasis) within the next 24 months.
Why that high (in brief):
- FDA border tools just got sharper. On Sept 5, 2025 FDA created a GLP-1 “green list” import alert (IA 66-80) so CBP can automatically detain GLP-1-class APIs from unverified foreign sources; only pre-vetted manufacturers’ shipments are waved through. That raises the odds upstream APIs for tri-agonists like retatrutide get stopped. (U.S. Food and Drug Administration)
- FDA is explicitly targeting retatrutide sold as “for research only.” FDA’s consumer safety page now names retatrutide alongside semaglutide/tirzepatide as products illegally sold under RUO/“not for human consumption” disclaimers, and notes warning letters to such vendors. (U.S. Food and Drug Administration)
- Recent enforcement pattern: FDA has already warned peptide vendors (e.g., Xcel Peptides, Swisschems, Summit Research, Prime Peptides) for GLP-1 analog sales marketed as RUO but intended for human use; several of those sites also offered retatrutide. This signals active policing of the exact channel you mention. (Reuters)
- Small-parcel loophole largely closed. The U.S. has ended de minimis duty-free treatment for low-value imports (globally as of Aug 29, 2025), pushing small packages into full customs processing—making detentions of suspicious drug shipments easier. (U.S. Customs and Border Protection)
- Post-shortage crackdown model. As FDA resolved GLP-1 shortages, it ended enforcement discretion and tightened compounding rules—an approach likely to carry over to newer incretins as they progress (retatrutide is deep in trials). (U.S. Food and Drug Administration)
What “restrict” will likely look like
- More DWPE detentions at ports (APIs and finished vials);
- Warning letters/domain takedowns for sellers marketing RUO peptides for human use;
- Carrier scrutiny and higher costs/delays as parcels face full entry and duties.
Notes specific to Oasis-style sellers
- Sites are already offering retatrutide under euphemisms like “GLP3(R)” with RUO disclaimers—exactly the pattern FDA flags. If their upstream API isn’t on the “green list”, or if any human-use marketing is found, shipments are at risk. (myoasislabs.com)
What could move the odds:
- Up: a high-profile safety incident; Lilly filing/approval (typically spurs stricter enforcement against knock-offs).
- Down: policy reversal on de minimis (unlikely soon) or FDA resource reprioritization.
If you want, I can track new import alerts or warning letters and ping you when something changes.
I really hope synthetic biology can help save the day [see the uOttawa students who grew GLP1s with simple eukaryotes…]
I’d also advise stockpiling up b/c there can be “surge levels” of interest in GLP1s at a later date [there are so many benefits to reducing food consumption during critical intervals of time, but one of the big ones is that you reduce your rates of food poisoning, and biosecurity people (eg kevin esvelt) note that the chance of “biorisk” in the near-term can exponentially amplify soon]. Some biorisk comes from food [not just microplastics, but pathogens engineered to be hardier than previous ones]
Cremieux has already made offlabel use of GLP1s way “less weird” by commenting on how they have made many people way more attractive than they otherwise would be. I know a lot of his followers are also kind of right-wing, but I don’t know how much this is going to matter for leverage over the administration (even though if risk of any kind amplifies soon, we will have to be in MUCH stronger control over our food/water inputs to prevent poisoning of all kinds, and retatrutide makes it way easier to have control over these inputs).
In some cases, saying you’re doing GLP1s also is now less weird than saying you do CR. More importantly it’s less misleading bc you can easily say you try CR and fail at it
[to be fair, most of the increased risk from excess food is still microplastic risk]
1 Like